^
    Back
    Association details:
    Biomarker:KMT2A rearrangement
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:bortezomib (Proteasome inhibitor) +
    Zolinza (vorinostat) (HDAC inhibitor) +
    dexamethasone (GCR agonist) +
    mitoxantrone (Topoisomerase II inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2023
    Title:

    823 Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study

    Published date:
    11/02/2023
    Excerpt:
    In this study, bortezomib and vorinostat were incorporated into an ALL chemotherapy backbone containing dexamethasone, mitoxantrone, and pegasparaginase during induction and reinduction chemotherapy cycles....The EFS and OS of KMT2Ar patients were 44.8% (9.5) and 62% (9.1) respectively. CIR and CID for KMT2Ar patients was 43.5% (9.6) and 7.2% (5) respectively. KMT2Ar patients ≥90 days at diagnosis had superior outcomes compared to their younger counterparts with 59.1% (10.5) EFS and 77.3% (8.9) OS....We conclude that the incorporation of bortezomib and vorinostat for treatment of infants with ALL was well tolerated. MRD responses in KMT2Ar patients were robust.
    Trial ID:
    NCT05848687